Uganda

The National Drug Authority (NDA), established under the National Drug Policy and Authority Act (Cap. 206) and its subsequent amendments, is the primary regulatory body responsible for the registration and quality assurance of health products in Uganda, including pharmaceuticals, medical devices, diagnostics, and increasingly, digital health solutions. The NDA operates under the Ministry of Health and enforces standards across the full product lifecycle, from pre-market approval through post-market surveillance. Applicants must submit a formal registration application, pay the requisite fees, and undergo a technical review process that assesses safety, efficacy, and quality. Products may also be eligible for expedited pathways if they have received prior approval from a recognized stringent regulatory authority (SRA) such as the US FDA, EMA, or WHO prequalification, which can significantly reduce review timelines.

All registration dossiers submitted to the NDA must generally conform to the Common Technical Document (CTD) format, and the NDA also accepts dossiers aligned with the African Common Technical Document (ACTD) format as promoted by the African Union Development Agency (AUDA-NEPAD). Applicants based outside Uganda are required to appoint a local authorized representative or registered importer who assumes regulatory responsibility within the country. The NDA has undertaken notable reforms in recent years, including alignment with the African Medicines Regulatory Harmonization (AMRH) initiative and participation in the African Medicines Agency (AMA) framework, aimed at streamlining cross-border approvals and reducing duplication of review efforts across the continent. Post-market surveillance requirements, adverse event reporting obligations, and product labeling standards in English are strictly enforced.

Public sector procurement of health products in Uganda is centralized primarily through the National Medical Stores (NMS), a government parastatal under the Ministry of Health responsible for the warehousing and distribution of medicines, medical devices, diagnostics, and other health commodities to government health facilities across all levels of the health system. The Ministry of Health sets national health commodity requirements through the Essential Medicines and Health Supplies List (EMHSLU), and procurement activities are governed by the Public Procurement and Disposal of Public Assets Authority (PPDA) framework, which mandates competitive tendering processes for public contracts. Uganda Health Marketing Group (UHMG) and the Joint Medical Stores (JMS), a faith-based nonprofit, also play significant roles in health commodity distribution, particularly to private not-for-profit and lower-level facilities. Suppliers seeking access to public tenders must be registered with the NDA and meet local regulatory and business registration requirements.

Uganda's health sector is substantially supported by international donors and multilateral procurement channels, which represent a significant share of total health commodity financing. Key partners include the Global Fund to Fight AIDS, Tuberculosis and Malaria; the United States Government through USAID and PEPFAR mechanisms; Gavi, the Vaccine Alliance for immunization commodities; and UNICEF Supply Division for essential medicines and diagnostics. Many of these donor-funded procurements require WHO prequalification or SRA approval as a precondition for product eligibility, making international regulatory standing a critical market access factor. Uganda has also articulated ambitions to promote local manufacturing as part of its broader industrialization agenda, with the Ministry of Health and Ministry of Trade supporting preferential policies for locally manufactured health products, aligned with the African Union's Pharmaceutical Manufacturing Plan for Africa (PMPA). However, implementation of local preference margins in procurement remains nascent and is subject to evolving policy guidance.